Asthma Forecast and Market Analysis to 2024

  • ID: 4489115
  • Report
  • 680 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Asthma is a chronic respiratory disease characterized by recurrent breathlessness and wheezing, which occur in acute events known as attacks. These attacks can vary significantly in frequency and severity, and consist of swelling of the lining of the bronchial tubes, which narrows airways and results in a reduction of airflow into and out of the lungs. Collaborators of the Global Initiative for Asthma believe that as many as 300 million people worldwide are greatly impacted by asthma in their daily lives, whether through asthma symptoms not allowing them to undertake simple day-to-day activities or through being unable to complete assigned tasks at work.

Recent events and opinion
  • Biologic therapies will drive growth in the asthma market despite generic erosion of key ICS/LABA combinations.
  • The author’s survey of 221 physicians sheds light on treatment patterns and prescribing influences.
  • There were an estimated 51.3 million diagnosed prevalent cases in 2016; this is predicted to rise due to population growth.
  • Competition for eosinophilic asthma is intensifying with the recent approval of Fasenra, the third-to-market IL-5 inhibitor.
  • Bolstered by strong clinical data, Dupixent is poised to have a large impact on the biologic therapies market.
  • Payers’ fear of the budget impact of newly approved IL-5 inhibitors will prompt tighter access control.
Note: Product cover images may vary from those shown
2 of 3
1 TABLE OF CONTENTS (Forecast, Treatment, Epidemiology and Pipeline Datapacks included)
  • FORECAST: ASTHMA IN THE US, JAPAN, AND 5EU (Published on 16 February 2018)
  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: ADVAIR
  • PRODUCT PROFILE: BREO ELLIPTA
  • PRODUCT PROFILE: CINQAIR
  • PRODUCT PROFILE: DULERA
  • PRODUCT PROFILE (LATE STAGE): DUPIXENT
  • PRODUCT PROFILE: FASENRA
  • PRODUCT PROFILE: FLUTIFORM
  • PRODUCT PROFILE: NUCALA
  • PRODUCT PROFILE (LATE STAGE): QVM149
  • PRODUCT PROFILE: SINGULAIR
  • PRODUCT PROFILE: SPIRIVA
  • PRODUCT PROFILE: SYMBICORT
  • PRODUCT PROFILE (LATE STAGE): TRELEGY ELLIPTA
  • PRODUCT PROFILE: XOLAIR
2 TREATMENT: ASTHMA (Published on 19 February 2018)
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • COUNTRY TREATMENT TREES
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • IMPACT OF GENERICS
  • UNMET NEEDS IN ASTHMA
3 EPIDEMIOLOGY: ASTHMA (Published on 05 January 2018)
  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES
4 MARKETED DRUGS: ASTHMA (Published on 16 February 2018)
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ADVAIR
  • PRODUCT PROFILE: BREO ELLIPTA
  • PRODUCT PROFILE: CINQAIR
  • PRODUCT PROFILE: DULERA
  • PRODUCT PROFILE: FASENRA
  • PRODUCT PROFILE: FLUTIFORM
  • PRODUCT PROFILE: NUCALA
  • PRODUCT PROFILE: SINGULAIR
  • PRODUCT PROFILE: SPIRIVA
  • PRODUCT PROFILE: SYMBICORT
  • PRODUCT PROFILE: XOLAIR
5 ASTHMA PRICING, REIMBURSEMENT, AND ACCESS (Published on 05 May 2016)
  • EXECUTIVE SUMMARY
  • MARKET CONTEXT
  • GLOBAL PAYER INSIGHTS
  • US PRICING
  • US PAYER INSIGHTS
  • US REIMBURSEMENT
  • JAPAN
  • FIVE MAJOR EU MARKETS PRICING
  • FIVE MAJOR EU MARKETS PAYER INSIGHTS
  • GENERIC ICS/LABA INHALERS IN THE FIVE MAJOR EU MARKETS
  • FRANCE
  • GERMANY
  • ITALY
  • SPAIN
  • UK
  • METHODOLOGY
6 PIPELINE: ASTHMA (Published on 16 February 2018)
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • PRODUCT PROFILE (LATE STAGE): DUPIXENT
  • PRODUCT PROFILE (LATE STAGE): QVM149
  • PRODUCT PROFILE (LATE STAGE): TRELEGY ELLIPTA
List of Figures
Figure 1: Asthma - current and future market dynamics analysis
Figure 2: The author’s assessment summary of key marketed and pipeline drugs for asthma
Figure 3: Asthma sales across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: Asthma sales across the US, Japan, and five major EU markets, by class, 2017-26
Figure 5: Sales of IL inhibitors across the US, Japan, and five major EU markets, by drug, 2017-26
Figure 6: Sales of ICS/LABA therapies across the US, Japan, and five major EU markets, by drug, 2017-26
Figure 7: Triple therapy sales across the US, Japan, and five major EU markets, by drug, 2017-26
Figure 8: Patient-based asthma forecast methodology
Figure 9: Price sources and calculations, by country
Figure 10: Advair for asthma - SWOT analysis
Figure 11: The author’s drug assessment summary of Advair in asthma
Figure 12: The author’s drug assessment summary of Advair in asthma
Figure 13: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 14: Breo Ellipta for asthma - SWOT analysis
Figure 15: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 16: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 17: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 18: Cinqair for asthma - SWOT analysis
Figure 19: The author’s drug assessment summary of Cinqair in asthma
Figure 20: The author’s drug assessment summary of Cinqair in asthma
Figure 21: Cinqair sales for asthma across the US and five major EU markets, by country, 2017-26
Figure 22: Dulera for asthma - SWOT analysis
Figure 23: The author’s drug assessment summary of Dulera in asthma
Figure 24: The author’s drug assessment summary of Dulera in asthma
Figure 25: Dulera sales for asthma in the US, 2017-26
Figure 26: Dupixent for asthma - SWOT analysis
Figure 27: The author’s drug assessment summary of Dupixent in asthma
Figure 28: The author’s drug assessment summary of Dupixent in asthma
Figure 29: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 30: Fasenra for asthma - SWOT analysis
Figure 31: The author’s drug assessment summary of Fasenra in asthma
Figure 32: The author’s drug assessment summary of Fasenra in asthma
Figure 33: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 34: Flutiform for asthma - SWOT analysis
Figure 35: The author’s drug assessment summary of Flutiform in asthma
Figure 36: The author’s drug assessment summary of Flutiform in asthma
Figure 37: Flutiform sales for asthma across Japan and the five major EU markets, by country, 2017-26
Figure 38: Nucala for asthma - SWOT analysis
Figure 39: The author’s drug assessment summary of Nucala in asthma
Figure 40: The author’s drug assessment summary of Nucala in asthma
Figure 41: Nucala sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 42: QVM149 for asthma - SWOT analysis
Figure 43: The author’s drug assessment summary of QVM149 in asthma
Figure 44: The author’s drug assessment summary of QVM149 in asthma
Figure 45: QVM149 sales for asthma across Japan and the five major EU markets, by country, 2017-26
Figure 46: Singulair for asthma - SWOT analysis
Figure 47: The author’s drug assessment summary of Singulair in asthma
Figure 48: The author’s drug assessment summary of Singulair in asthma
Figure 49: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 50: Spiriva for asthma - SWOT analysis
Figure 51: The author’s drug assessment summary of Spiriva in asthma
Figure 52: The author’s drug assessment summary of Spiriva in asthma
Figure 53: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 54: Symbicort for asthma - SWOT analysis
Figure 55: The author’s drug assessment summary of Symbicort in asthma
Figure 56: The author’s drug assessment summary of Symbicort in asthma
Figure 57: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 58: Trelegy Ellipta for asthma - SWOT analysis
Figure 59: The author’s drug assessment summary of Trelegy Ellipta in asthma
Figure 60: The author’s drug assessment summary of Trelegy Ellipta in asthma
Figure 61: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 62: Xolair for asthma - SWOT analysis
Figure 63: The author’s drug assessment summary of Xolair in asthma
Figure 64: The author’s drug assessment summary of Xolair in asthma
Figure 65: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 66: Percentage of asthma patients remaining undiagnosed, by severity and country (%)
Figure 67: Severity of diagnosed asthma patients in the US, Japan, and five major EU markets, by country (%), 2017
Figure 68: Trend in 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016-36
Figure 69: Absolute change in 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016-36
Figure 70: Advair for asthma - SWOT analysis
Figure 71: The author’s drug assessment summary of Advair in asthma
Figure 72: The author’s drug assessment summary of Advair in asthma
Figure 73: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 74: Breo Ellipta for asthma - SWOT analysis
Figure 75: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 76: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 77: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 78: Cinqair for asthma - SWOT analysis
Figure 79: The author’s drug assessment summary of Cinqair in asthma
Figure 80: The author’s drug assessment summary of Cinqair in asthma
Figure 81: Cinqair sales for asthma across the US and five major EU markets, by country, 2017-26
Figure 82: Dulera for asthma - SWOT analysis
Figure 83: The author’s drug assessment summary of Dulera in asthma
Figure 84: The author’s drug assessment summary of Dulera in asthma
Figure 85: Dulera sales for asthma in the US, 2017-26
Figure 86: Fasenra for asthma - SWOT analysis
Figure 87: The author’s drug assessment summary of Fasenra in asthma
Figure 88: The author’s drug assessment summary of Fasenra in asthma
Figure 89: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 90: Flutiform for asthma - SWOT analysis
Figure 91: The author’s drug assessment summary of Flutiform in asthma
Figure 92: The author’s drug assessment summary of Flutiform in asthma
Figure 93: Flutiform sales for asthma across Japan and the five major EU markets, by country, 2017-26
Figure 94: Nucala for asthma - SWOT analysis
Figure 95: The author’s drug assessment summary of Nucala in asthma
Figure 96: The author’s drug assessment summary of Nucala in asthma
Figure 97: Nucala sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 98: Singulair for asthma - SWOT analysis
Figure 99: The author’s drug assessment summary of Singulair in asthma
Figure 100: The author’s drug assessment summary of Singulair in asthma
Figure 101: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 102: Spiriva for asthma - SWOT analysis
Figure 103: The author’s drug assessment summary of Spiriva in asthma
Figure 104: The author’s drug assessment summary of Spiriva in asthma
Figure 105: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 106: Symbicort for asthma - SWOT analysis
Figure 107: The author’s drug assessment summary of Symbicort in asthma
Figure 108: The author’s drug assessment summary of Symbicort in asthma
Figure 109: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 110: Xolair for asthma - SWOT analysis
Figure 111: The author’s drug assessment summary of Xolair in asthma
Figure 112: The author’s drug assessment summary of Xolair in asthma
Figure 113: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 114: Dupixent for asthma - SWOT analysis
Figure 115: The author’s drug assessment summary of Dupixent in asthma
Figure 116: The author’s drug assessment summary of Dupixent in asthma
Figure 117: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 118: QVM149 for asthma - SWOT analysis
Figure 119: The author’s drug assessment summary of QVM149 in asthma
Figure 120: The author’s drug assessment summary of QVM149 in asthma
Figure 121: QVM149 sales for asthma across Japan and the five major EU markets, by country, 2017-26
Figure 122: Trelegy Ellipta for asthma - SWOT analysis
Figure 123: The author’s drug assessment summary of Trelegy Ellipta in asthma
Figure 124: The author’s drug assessment summary of Trelegy Ellipta in asthma
Figure 125: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Exchange rates used for calculating prices
Table 2: Primary care physicians and pulmonologists surveyed for the asthma primary research study, 2017
Table 3: Advair drug profile
Table 4: Advair Diskus pivotal trial data in asthma
Table 5: Advair HFA pivotal trial data in asthma
Table 6: Advair late-phase trial data in asthma
Table 7: Advair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 8: Breo Ellipta drug profile
Table 9: Breo Ellipta pivotal trial data in asthma
Table 10: Breo Ellipta late-phase trial data in asthma
Table 11: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 12: Cinqair drug profile
Table 13: Cinqair pivotal Phase III data in asthma
Table 14: Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017-26
Table 15: Dulera drug profile
Table 16: Dulera pivotal trial data in asthma
Table 17: Dulera Phase IV trial in asthma
Table 18: Dulera sales for asthma in the US ($m), 2017-26
Table 19: Dupixent drug profile
Table 20: Dupixent Phase III data in asthma
Table 21: Dupixent Phase III trials in asthma
Table 22: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 23: Fasenra drug profile
Table 24: Fasenra Phase III trials in asthma
Table 25: Ongoing Phase III trials for Fasenra in asthma
Table 26: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 27: Flutiform drug profile
Table 28: Flutiform pivotal trial data in asthma
Table 29: Flutiform Phase III trials in asthma
Table 30: Flutiform sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
Table 31: Nucala drug profile
Table 32: Nucala pivotal trial data in asthma
Table 33: Nucala late-phase trial data in asthma
Table 34: Nucala Phase III trials in asthma
Table 35: Nucala sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 36: QVM149 drug profile
Table 37: QVM149 Phase III trials in asthma
Table 38: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
Table 39: Singulair drug profile
Table 40: Singulair pivotal trial data in asthma
Table 41: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 42: Spiriva drug profile
Table 43: Spiriva pivotal trial data in asthma
Table 44: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 45: Symbicort drug profile
Table 46: Symbicort pivotal trial data in asthma
Table 47: Symbicort late-phase trial data in asthma
Table 48: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 49: Trelegy Ellipta drug profile
Table 50: Trelegy Ellipta Phase III trials in asthma
Table 51: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 52: Xolair drug profile
Table 53: Xolair pivotal trial data in asthma
Table 54: Xolair late-phase trial data in asthma
Table 55: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 56: Physicians surveyed for the asthma primary research study, 2017
Table 57: ICD-10 codes associated with asthma
Table 58: Classification of asthma in patients aged =12 years who are not taking long-term control medications, by impairment and risk
Table 59: Classification of patients after asthma becomes well controlled, by lowest level of treatment required to maintain control
Table 60: Severity of diagnosed asthma patients in the US, Japan, and five major EU markets, by country (%), 2017
Table 61: Branded therapies available for asthma across the US, Japan, and five major EU markets
Table 62: Global Initiative for Asthma stepwise approach for adjusting treatment of asthma
Table 63: Percentage of respondents using each set of guidelines for treatment of asthma, by country (%)
Table 64: Management of asthma patients in the US, Japan, and five major EU markets, by country, disease severity, and type of healthcare professional (%)
Table 65: Percentage of patients lost to follow-up*, by severity and country (%)
Table 66: Proportion of annual prescriptions filled, by severity and country (%)
Table 67: Prescribing influences in the treatment of asthma in the US, Japan, and five major EU markets, by country (%)
Table 68: Expected patient switching to inhaled generics in the US, Japan, and five major EU markets, by device type (%)
Table 69: Treatment challenges in asthma
Table 70: Patient compliance with asthma treatments, by drug formulation and country (%)
Table 71: Sources used for the epidemiological analysis of diagnosed asthma in the US, Japan, and five major EU markets, by country
Table 72: Global Initiative for Asthma guidelines on severity
Table 73: 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016-36
Table 74: Age- and gender-specific 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016
Table 75: 12-month prevalent cases of asthma in the US, Japan, and five major EU markets, by severity and country, 2016
Table 76: Validation of asthma prevalence forecast estimates against benchmark estimates
Table 77: Profiled key marketed drugs for asthma
Table 78: Advair drug profile
Table 79: Advair Diskus pivotal trial data in asthma
Table 80: Advair HFA pivotal trial data in asthma
Table 81: Advair late-phase trial data in asthma
Table 82: Advair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 83: Breo Ellipta drug profile
Table 84: Breo Ellipta pivotal trial data in asthma
Table 85: Breo Ellipta late-phase trial data in asthma
Table 86: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 87: Cinqair drug profile
Table 88: Cinqair pivotal Phase III data in asthma
Table 89: Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017-26
Table 90: Dulera drug profile
Table 91: Dulera pivotal trial data in asthma
Table 92: Dulera Phase IV trial in asthma
Table 93: Dulera sales for asthma in the US ($m), 2017-26
Table 94: Fasenra drug profile
Table 95: Fasenra Phase III trials in asthma
Table 96: Ongoing Phase III trials for Fasenra in asthma
Table 97: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 98: Flutiform drug profile
Table 99: Flutiform pivotal trial data in asthma
Table 100: Flutiform Phase III trials in asthma
Table 101: Flutiform sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
Table 102: Nucala drug profile
Table 103: Nucala pivotal trial data in asthma
Table 104: Nucala late-phase trial data in asthma
Table 105: Nucala Phase III trials in asthma
Table 106: Nucala sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 107: Singulair drug profile
Table 108: Singulair pivotal trial data in asthma
Table 109: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 110: Spiriva drug profile
Table 111: Spiriva pivotal trial data in asthma
Table 112: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 113: Symbicort drug profile
Table 114: Symbicort pivotal trial data in asthma
Table 115: Symbicort late-phase trial data in asthma
Table 116: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 117: Xolair drug profile
Table 118: Xolair pivotal trial data in asthma
Table 119: Xolair late-phase trial data in asthma
Table 120: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 121: Marketed products and approved indications for asthma in the US, Japan, and five major EU markets
Table 122: Pivotal safety and efficacy clinical trials for late-stage pipeline candidates in asthma
Table 123: US pricing of key marketed drugs
Table 124: Asthma and chronic obstructive pulmonary disease spend by payers, 2014
Table 125: Top 10 asthma and chronic obstructive pulmonary disease drug spend by Express Scripts members
Table 126: Spend on the top three asthma and chronic obstructive pulmonary disease drugs by Medicare Part D beneficiaries, 2013
Table 127: Global Initiative for Asthma treatment guidelines
Table 128: Formulary placement of asthma drugs in selected commercial formularies
Table 129: Formulary placement of asthma drugs in the top five 2016 Medicare Part D formularies
Table 130: Formulary placement of asthma drugs in selected large Medicaid states’ preferred drug lists
Table 131: CVS Caremark’s and Express Scripts’ formulary-excluded asthma drugs
Table 132: Express Scripts’ TRICARE formulary placement of asthma drugs
Table 133: Prior authorization criteria for asthma drugs by major health insurers and pharmacy benefit managers
Table 134: Pricing premiums given to medicines that can demonstrate benefit over comparators
Table 135: Pricing of key marketed asthma drugs in Japan
Table 136: Price calculation methodologies for asthma drugs launched in Japan after 2008
Table 137: Annual treatment cost of asthma drugs in the five major EU markets
Table 138: Access controls for asthma medications in the five major EU markets
Table 139: Availability and substitutability of branded generic inhalers in the five major EU markets
Table 140: List price differential between branded ICS/LABAs and branded generics in the five major EU markets
Table 141: Market access levers impacting ICS/LABA generic inhaler uptake in the five major EU markets
Table 142: Transparency Committee’s ASMR ratings and pricing implications
Table 143: Transparency Committee’s SMR ratings and pricing implications
Table 144: Transparency Committee’s assessment of asthma treatments
Table 145: G-BA assessment of key asthma therapy
Table 146: Reimbursement conditions for asthma treatments in Italy
Table 147: Local formulary decisions for asthma drugs
Table 148: Therapeutic positioning reports for asthma drugs in Spain
Table 149: Spain regional assessments of asthma drugs
Table 150: NICE assessments of key asthma therapies
Table 151: CCG formulary inclusions for key asthma drugs
Table 152: SMC decisions on key asthma therapies
Table 153: SIGN asthma treatment guidelines
Table 154: Price sources and calculations for the US
Table 155: Price sources and calculations for the EU
Table 156: Exchange rates used for calculating branded drug prices
Table 157: Late-phase pipeline products in development for asthma
Table 158: Dupixent drug profile
Table 159: Dupixent Phase III data in asthma
Table 160: Dupixent Phase III trials in asthma
Table 161: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 162: QVM149 drug profile
Table 163: QVM149 Phase III trials in asthma
Table 164: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
Table 165: Trelegy Ellipta drug profile
Table 166: Trelegy Ellipta Phase III trials in asthma
Table 167: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll